NEFL and myeloid sarcoma: Applying these reference limits to a MS population included in the Multiple Sclerosis Partners Advancing Technology and Health Solutions network (MS PATHS), elevated NfL concentrations (i.e., diagnostic sensitivity) were found in 3.7–30.9% using the 95th percentile cutoff and in 2.5–14% using the 97.5th percentile cut-off.67